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background: Coronary sinus (CS) blood is obtainable during implantation of cardiac resynchronization therapy (CRT). We aimed to determine 
whether CS or peripheral venous (PV) biomarkers are predictive of CRT response and major adverse cardiovascular events (MACE) using single and 
multi-marker strategies.
methods: In 73 patients (age 68±12; 83% male; ejection fraction 27±7%) with CS and PV blood drawn simultaneously at the time of CRT 
implantation and 114 patients with PV blood, we measured amino-terminal pro-B type natriuretic peptide (NT-proBNP), galectin-3 (gal-3), and 
soluble (s)ST2 levels. NT-proBNP concentrations>2000 pg/mL, gal-3>25.9 ng/mL, and sST2>35 ng/mL were considered positive.
results: NT-proBNP concentrations were 20% higher in the CS than periphery, while gal-3 and sST2 were 10% higher in periphery than CS (all 
p<0.001). There were 45% CRT non-responders at 6 months and 22% MACE at 2 years. Triple positive CS values yielded the highest specificity of 
95% for predicting CRT non-response and predictive of MACE, while PV strategy was not (Figure). Compared to triple negative CS patients, those 
with triple positive CS results had a 14-fold increase in adjusted hazards (p≤0.04). Even when examined in a larger CRT cohort of 114 patients, PV 
strategies were not predictive of MACE.
conclusions: In patients undergoing CRT, biomarkers sampled from the CS are highly specific for identifying CRT non-response and superior to PV 
strategies for predicting MACE.
 
